Surveys & insights
You will find here Forvis Mazars surveys and insights.
Forvis Mazars HR-pedia 2026 - your guide to HR and payroll in Poland
A practical guide to HR and payroll in Poland, covering key employer obligations, payroll rules and compliance requirements.
C-suite barometer 2026: adapting in uncertainty
Our latest study uncovers a business world embracing change, investing in technology and people, and reimagining strategies to stay ahead of disruption and competition. Success now rests on adaptability as much as ambition.
Investing in CEE: Inbound M&A report 2025/2026
Global private equity outlook 2026: Exploring new investment direction
The Forvis Mazars global private equity outlook 2026 delivers exclusive insights from over 800 private equity professionals across regions, sectors and investment strategies. Explore our global report and insights into how investor priorities are evolving amid changing market conditions.
Forvis Mazars CEE deal advisory highlights 2025
Our deal advisory highlights feature a selection of projects that we advised on throughout the region in 2025.
New Forvis Mazars research identifies compliance, accuracy and visibility to reshape payroll performance across Europe
Based on the views of more than 1,000 payroll, HR and finance leaders from 13 markets, the 'Compliance, accuracy, and visibility: the 3 non-negotiables in modern European payroll' report reveals how payroll has evolved from a transactional necessity into a strategic pillar of organisational trust, data governance and people experience.
CEE banking outlook 2025
Our new study, the CEE Strategic resilience in banking: outlook 2025, combines independent market intelligence with practical insights from financial services professionals advising banks across the region. The report examines trends in profitability, capital adequacy, regulatory evolution, digitalisation, securitisation and ESG integration across six CEE markets.
CEE insurance outlook 2025
Our new "CEE strategic resilience in insurance: outlook 2025" reveals that the region’s insurers have expanded non-life premiums from €18 billion in 2018 to €28.5 billion in 2024, a 58% surge that outpaces many mature Western markets.
Report: Re-shoring life sciences for a sustainable future
The pandemic, geopolitical tensions and the climate emergency have revealed the vulnerabilities of Europe’s life sciences industry. Relocating pharmaceutical and medtech production is no longer a choice but a strategic necessity to safeguard sovereignty, strengthen competitiveness and ensure long-term sustainability.
C-suite barometer: life sciences and pharmaceuticals sector view
In a year marked by global uncertainty, shifting regulations and fast-moving innovation, leaders in the life sciences and pharmaceuticals sector are redefining their strategic priorities. Drawing on insights from executives from across more than 35 countries, our latest report captures how sector players are navigating complexity, investing in growth and positioning themselves for long-term success in a competitive landscape.